Ensysce Biosciences Overview
- Year Founded
-
2003
- Status
-
Public
- Employees
-
10
- Stock Symbol
-
ENSC
- Investments
-
3
- Share Price
-
$0.36
- (As of Friday Closing)
Ensysce Biosciences General Information
Description
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
Contact Information
Website
www.ensysce.comCorporate Office
- 7946 Ivanhoe Avenue
- Suite 201
- La Jolla, CA 92037
- United States
Corporate Office
- 7946 Ivanhoe Avenue
- Suite 201
- La Jolla, CA 92037
- United States
Ensysce Biosciences Stock Performance
As of 20-Nov-2026, Ensysce Biosciences’s stock price is $0.36. Its current market cap is $7M with 19.5M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.36 | $0.36 | $0.23 - $1.85 | $7M | 19.5M | 500K | -$7.70 |
Ensysce Biosciences Financials Summary
As of 30-Sep-2026, Ensysce Biosciences has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 7,281 | 1,728 | 6,527 | 1,897 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (90,970) | (10,151) | (6,697) | (10,272) |
| Net Income | (91,008) | (10,176) | (7,987) | (10,613) |
| Total Assets | 30,953 | 7,452 | 5,597 | 2,708 |
| Total Debt | 155 | 307 | 302 | 855 |
Ensysce Biosciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Ensysce Biosciences Comparisons
Industry
Financing
Details
Ensysce Biosciences Competitors (51)
One of Ensysce Biosciences’s 51 competitors is Merck & Co., a Corporation company based in Rahway, NJ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Merck & Co. | Corporation | Rahway, NJ | ||||
| Mitochon Pharmaceuticals | Venture Capital-Backed | Blue Bell, PA | ||||
| Acura Pharmaceuticals | Formerly VC-backed | Palatine, IL | ||||
| Indivior | Corporate Backed or Acquired | North Chesterfield, VA | ||||
| Fresenius Kabi | Corporation | Bad Homburg, Germany |
Ensysce Biosciences Patents
Ensysce Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024248178-A1 | Methadone active agents and methods of use thereof | Pending | 27-Mar-2023 | ||
| EP-4688733-A2 | Methadone active agents and methods of use thereof | Pending | 27-Mar-2023 | ||
| US-20260226000-A1 | Methadone active agents and methods of use thereof | Pending | 27-Mar-2023 | ||
| WO-2024206289-A2 | Methadone active agents and methods of use thereof | Inactive | 27-Mar-2023 | ||
| WO-2024206289-A3 | Methadone active agents and methods of use thereof | Inactive | 27-Mar-2023 | C07C271/20 |
Ensysce Biosciences Signals
Ensysce Biosciences Acquisitions (3)
Ensysce Biosciences’s most recent deal was a Merger/Acquisition with Cy Biopharma. The deal was made on 05-Aug-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Cy Biopharma | 05-Aug-2026 | Merger/Acquisition | Drug Discovery | ||
| Leisure Acquisition | 01-Jul-2021 | Merger/Acquisition | Special Purpose Acquisition Company (SPAC) | ||
| Signature Therapeutics | 31-Dec-2015 | Merger/Acquisition | Drug Discovery |
Ensysce Biosciences ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Ensysce Biosciences Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Cy Biopharma | Baar, Switzerland | 2020 | |
| Covistat |
Ensysce Biosciences FAQs
-
When was Ensysce Biosciences founded?
Ensysce Biosciences was founded in 2003.
-
Where is Ensysce Biosciences headquartered?
Ensysce Biosciences is headquartered in La Jolla, CA.
-
What is the size of Ensysce Biosciences?
Ensysce Biosciences has 10 total employees.
-
What industry is Ensysce Biosciences in?
Ensysce Biosciences’s primary industry is Drug Discovery.
-
Is Ensysce Biosciences a private or public company?
Ensysce Biosciences is a Public company.
-
What is Ensysce Biosciences’s stock symbol?
The ticker symbol for Ensysce Biosciences is ENSC.
-
What is the current stock price of Ensysce Biosciences?
As of 20-Nov-2026 the stock price of Ensysce Biosciences is $0.36.
-
What is the current market cap of Ensysce Biosciences?
The current market capitalization of Ensysce Biosciences is $7M.
-
Who are Ensysce Biosciences’s competitors?
Merck & Co., Mitochon Pharmaceuticals, Acura Pharmaceuticals, Indivior, and Fresenius Kabi are some of the 51 competitors of Ensysce Biosciences.
-
What is Ensysce Biosciences’s annual earnings per share (EPS)?
Ensysce Biosciences’s EPS for 12 months was -$7.70.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process